Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Diagnostics page still available :
https://avacta.com/diagnostics/
This is new : https://avacta.com/precision-immuno-peptide-drug-conjugate/
Yes lots added easier to look at this page
https://avacta.com/page-sitemap.xml
Note this Glossary added today on website
https://avacta.com/wp-content/uploads/2024/04/Glossary.pdf
https://avacta.com/investors/investor-resources/
Thanks Almostrich : Nice post lot going on at Avatca :
Would like think AffyXell Therapeutics JV could also be a very promising Avacta asset .
https://www.koreabiomed.com/news/articleViewAmp.html?idxno=23706
----------------------------------
"Jeon, the outgoing co-CEO, is expected to lead Daewoong Investment and AffyXell Therapeutics, a cell and gene therapy development company co-founded by Daewoong and the UK biotech firm Avacta Group in 2020. This transition marks a new chapter in Daewoong Pharmaceutical's pursuit of innovation and global expansion.
Under this restructured leadership, the company stressed that Park will oversee global operations and R&D efforts, while Lee, who was appointed in 2022, will focus on domestic business and marketing."
Note LD appointment in Germany
"
David Wilson likes this
Lena KastlLena Kastl
• 3rd+ • 3rd+
Managing Director bei Launch Diagnostics Deutschland GmbHManaging Director bei Launch Diagnostics Deutschland GmbH
21h • 21h •
Follow
Ich habe einen neuen Job und arbeite jetzt als Geschäftsführer bei Launch Diagnostics Deutschland GmbH
Rate this translation
I have a new job and am now working as Managing Director at Launch Diagnostics Deutschland GmbH "
FYI :
https://2024conventions.com/eccmid/?msclkid=57856c947d451926e8650a9ba4f63381&utm_source=bing&utm_medium=cpc&utm_campaign=2024conventions.com&utm_term=eccmid%202024&utm_content=ECCMID
FYI Good to see LD & Coris attending
------
https://www.linkedin.com/company/launch-diagnostics/
https://www.linkedin.com/company/coris-bioconcept/
Launch Diagnostics LimitedLaunch Diagnostics Limited
1,535 followers1,535 followers
2h • 2h •
At ECCMID 2024, a session will be held highlighting the increasing rate of STI’s, including syphilis in the over-45’s which has seen an 18% rise since 2019.
This shift in demographics signals a need for heightened awareness and targeted interventions, including enhanced surveillance testing of key populations, and education on the risks of unprotected sexual activity.
The AIX 1000 from Gold Standard Diagnostics is a fully automated RPR testing instrument, producing up to 192 screening or titration results in 90 minutes. The onboard camera with pattern recognition software ensures standardised interpretation, with archiving of all images for reviewing & training purposes.
For more information, please visit:
https://lnkd.in/eD-Ta2wK
or contact your local Territory Manager
#syphilis #launchdiagnostics #gsd #aix1000 #safesex
----------------
Also
Launch Diagnostics LimitedLaunch Diagnostics Limited
1,535 followers1,535 followers
1d • 1d •
The latest statistics relating to laboratory confirmed measles cases in England have been published in an updated epidemiological overview by UKHSA, increasing by 79 cases in the last week alone.
Launch Diagnostics offer products for both diagnosis of infection and the establishing of immunity to Measles. Visit our Measles spotlight page for more information, email us at enquiries@launchdiagnostics.com or speak to your local territory manager.
https://lnkd.in/epH_E3t5
#Diagnostics #Measles #PublicHealth
------------
CORIS BIOCONCEPTCORIS BIOCONCEPT
2,528 followers2,528 followers
1w • Edited • 1w • Edited •
Follow
ESCMID is pleased to host this high-level ECCMID affiliated event in partnership with the Global Leaders Group on Antimicrobial Resistance (GLG). They welcome you all to join them on 26 April 2024 from 15:30 to 19:00 CEST, Fira Gran Via (North Access), Barcelona, Spain. The event will also be live-streamed on the ESCMID Facebook and YouTube channels.
https://lnkd.in/e8zMenZm
The ESCMID-GLG high-level event will be preceded by an ESCMID organised "think tank" symposium on the importance of diagnostics in AMR, from 14:00 - 15:00 CEST.
And another one
https://avacta.com/about/scientific-resources/
https://avacta.com/about/scientific-resources/ 0 2024-04-04 15:26 +00:00
Another page updated -
https://avacta.com/therapeutics/precision/
https://avacta.com/therapeutics/precision/ 0 2024-04-04 15:03 +00:00
Sorry not sure what has been updated -
---------------------------
"Alastair Smith talks through the data in Avacta's AVA32 and AVA3996 posters, presented in October 2023 at the AACR-NCI-EORTC International Conference on Molecular Targets." not new but worth a listen if not seen before .
https://avacta.wistia.com/medias/1ylosp1feo
https://avacta.com/investors/investor-resources/
https://avacta.com/about/published-papers/
https://avacta.com/about/published-papers/ 0 2024-04-04 13:52 +00:00
https://avacta.com/investors/investor-resources/ 0 2024-04-04 13:53 +00:00
Quote from article "but peptide–drug conjugates continue to be investigated for their potential to deepen tumor penetration and expand target range," Avacta have a solution "Peptide Drug Conjugate, AVA6000 "
Courtesy of RAH twitter - Interesting article must be a reason Avacta highlighting " Peptide Drug Conjugate, AVA6000 " @ upcoming AACR .
https://www.nature.com/articles/s41587-024-02168-5
Quote " Yet constant naysayers pursue no less impossible dreams. Their fear and cynicism move nothing forward. They kill progress. How many cynics built empires, great cities, or powerful corporations?”-
Our resident Naysayers and grumblers have already given up they like to undermine your AVCT investment dreams, , "remember, they’re telling their story , not yours. "
Avacta not all doom & despair , certainly not reached " the be all & end all " stage yet , as naysayers like to predict .
Thankfully us “yay-sayers” still see considerable merit in the future value of Avacta assets /IP that will eventually be recognised by the wider investment community. Should also attract external partner interest willing to pay large £$ amounts for a licence to use Avacta exciting technology assets .
So Avacta main story yet to unfold "Avacta Therapeutics is a clinical-stage pioneer of next-generation cancer therapies, with a mission to transform treatment outcomes for cancer patients."
"The best thing about the future is that it comes one day at a time." important for old folks like me .
Good luck everyone
P.S. Note website update today : AACR RNS 06 MAR 2024 ( Like to play that video though ).
https://avacta.com/therapeutics/ 0 2024-04-02 11:46 +00:00
https://avacta.com/therapeutics/
It varies rough yardstick "Therapeutic area-specific estimates were highest for anticancer drugs (between $944 million and $4.54 billion).to get a drug to market " so " £200m " so far is certainly doing it on a shoestring . Hence the need for partner licences to help take Precision platform fowards which remains the company plan .(+ bonus is we retain AVA6000 inhouse and IP )
Need to wait & see from the next accounts as to Avacta Group Diagnostic revenue performance , anyway nice to see LD winning awards and proactive on linkedin
------------------------------------------------
https://www.launchdiagnostics.com/manufacturer/dynex/
https://www.launchdiagnostics.com/manufacturer/anatolia-geneworks/
------------
"Launch Diagnostics LimitedLaunch Diagnostics Limited
1,527 followers1,527 followers
1d • 1d •
Launch Diagnostics Ltd have been a distributor of DYNEX Technologies products since the year 2000. This month we are delighted to have received our second award in appreciation of commercial partnership excellence for 2023, having also received the award in 2022.
The Dynex DS2 ELISA processor can be used to automate serological testing for many markers across pathology, providing standardisation with little hands on time versus manual methods.
For more information please email enquiries@launchdiagnostics.com or contact your local territory manager.
------------
Launch Diagnostics LimitedLaunch Diagnostics Limited
1,527 followers1,527 followers
2h • 2h •
Since 2019, Launch Diagnostics have partnered with Anatolia Geneworks, distributing the Bosphore range of PCR assays for infectious diseases diagnostics.
With a broad range of over 150 assays available, Anatolia kits offer exceptional performance and quality. Whether it's in infectious diseases testing, research, or beyond, Anatolia Geneworks PCR kits deliver reliable results, empowering scientists and clinicians with the information needed for patient management.
Stay ahead in your field with Anatolia Geneworks PCR kits! For further information visit the Launch Diagnostics website, email us at enquiries@launchdiagnostics.com or speak to your local territory manager.
hashtag#PCR hashtag#MolecularDiagnostics hashtag#Innovation hashtag#AnatoliaGeneworks"
Of course i would prefer to be in paper profit current defict -58.41% - No expert running a company or the science or trading . Just buy & hold and will hang around to get a return. Give the management team the benefit of doubt to execute & deliver . Some obviously think differently fair enough .
Really appreciate those who take the time to share research/explain the science - Never filter what others post ,think . say & do up to them , hopefully see an SP upturn soon .
Good luck everyone.
Ha Ha : Be no senior management left at Avacta at this rate if everyone gets sacked . Think AVCT mean average SP over last 4 years approx £1.30 so folks had plenty of chances to get in/out -Think Avacta true asset IP value still to be recognised making progress though the clinic , good enough for me , the company will get there in the end .
Anyway GCD still active he did Linkedin like " Research and Development Spotlight Series – Episode 1"
"Michael Vinegrad
View Michael Vinegrad’s profile Out of network
· 3rd+
Group Communications Director at Avacta"
On website https://avacta.com/research-and-development-spotlight-series-episode-1/